Observational analysis shows improvements in red blood cell function in sickle cell disease patients post-transplant, suggesting biomarkers may predict clinical outcomes.
Key Points
Normalization of red blood cell function is observed three months after hematopoietic cell transplantation, reducing adhesion and sickling kinetics.
Significant decreases in FA-WB-VCAM from baseline to 1 year indicate improved red blood cell adhesion in engrafted patients.
Analysis employs dynamic sickling assays and evaluates sickling kinetics that correlate with hematopoietic cell transplantation success.
Findings suggest potential utility of biomarkers to gauge long-term effectiveness of gene therapy strategies in sickle cell disease.